# Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Study · id `cardio:ct-nct06577519` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06577519](<https://clinicaltrials.gov/study/NCT06577519>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06577519

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT06577519. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-06 (actual); primary completion 2026-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT06577519, source copy `cardio:ctgov-nct06577519-2026-07-27`, retrieved 2026-10-31)
- Started: 2024-09-06 (actual) (ClinicalTrials.gov record NCT06577519, source copy `cardio:ctgov-nct06577519-2026-07-27`, retrieved 2026-10-31)
- Primary completion: 2026-12-30 (anticipated) (ClinicalTrials.gov record NCT06577519, source copy `cardio:ctgov-nct06577519-2026-07-27`, retrieved 2026-10-31)
- Completion: 2026-12-30 (anticipated) (ClinicalTrials.gov record NCT06577519, source copy `cardio:ctgov-nct06577519-2026-07-27`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06577519, source copy `cardio:ctgov-nct06577519-2026-07-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06577519-2026-07-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
- Condition: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
- Intervention (Drug): Vicagrel
- Intervention (Drug): Clopidogrel
- Lead sponsor: Jiangsu vcare pharmaceutical technology co., LTD
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)

## Provenance

Content hash: 6f0203bfdc6bfffe76a0e896f9db809150faaccbaff89477e0a00bf7bda4a0ce
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
